Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Deciphering the mutational basis of anthracycline-induced cardiotoxicity in childhood cancer survivors
FY 2022-23
Summary
Supervisor: Dr. Adam Shlien, University of Toronto
Childhood cancer survivors (CCS) have an increased risk of heart failure. This is a direct result of the chemotherapy they received for their cancer. Anthracyclines are a major class of chemotherapy used to treat >50% of childhood cancers. Unfortunately, they damage the heart, leading to a condition known as anthracycline-induced cardiotoxicity (AIC). Despite active research, physicians still struggle to identify which patients will develop AIC and have inadequate treatment options to protect the heart against AIC. These shortcomings are due to a poor understanding of the mechanisms underlying AIC.
DNA codes the instructions for life. But when "typos" occur in DNA, this leads to the formation of mutations, which can then code the instructions for diseases. Chemotherapies are a well-known cause of mutations. However, anthracyclines cause mutations in the heart that leads to AIC remains unknown. To address this gap in our knowledge, I will study the DNA from the hearts of anthracycline-treated CCS to understand the origins of AIC better. Using sophisticated sequencing technologies and computational tools, I will determine the patterns and timing of mutations in the heart due to anthracyclines. Harnessing the information gained from this project will not only provide new mechanistic insights into AIC but will also equip physicians with the knowledge and tools to identify AIC patients earlier. It is simply not good enough to only treat a child's tumour; we need to learn how to anticipate and prevent the future heart complications resulting from their treatment. In doing so, we will ensure that every childhood cancer patient grows healthy and is a lifetime survivor of cancer.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
474425
Name
Mahendralingam Mathepan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Deciphering the mutational basis of anthracycline-induced cardiotoxicity in childhood cancer survivors
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Cancer Survivorship; Cardio-Oncology; Chemotherapy; Machine Learning; Mitochondrial Dna; Mosaicism; Mutational Signatures; Phylogenetics; Whole-Genome Sequencing
Abstract
Supervisor: Dr. Adam Shlien, University of Toronto
Childhood cancer survivors (CCS) have an increased risk of heart failure. This is a direct result of the chemotherapy they received for their cancer. Anthracyclines are a major class of chemotherapy used to treat >50% of childhood cancers. Unfortunately, they damage the heart, leading to a condition known as anthracycline-induced cardiotoxicity (AIC). Despite active research, physicians still struggle to identify which patients will develop AIC and have inadequate treatment options to protect the heart against AIC. These shortcomings are due to a poor understanding of the mechanisms underlying AIC.
DNA codes the instructions for life. But when "typos" occur in DNA, this leads to the formation of mutations, which can then code the instructions for diseases. Chemotherapies are a well-known cause of mutations. However, anthracyclines cause mutations in the heart that leads to AIC remains unknown. To address this gap in our knowledge, I will study the DNA from the hearts of anthracycline-treated CCS to understand the origins of AIC better. Using sophisticated sequencing technologies and computational tools, I will determine the patterns and timing of mutations in the heart due to anthracyclines. Harnessing the information gained from this project will not only provide new mechanistic insights into AIC but will also equip physicians with the knowledge and tools to identify AIC patients earlier. It is simply not good enough to only treat a child's tumour; we need to learn how to anticipate and prevent the future heart complications resulting from their treatment. In doing so, we will ensure that every childhood cancer patient grows healthy and is a lifetime survivor of cancer.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Mahendralingam, Mathepan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~